新一代铂铬合金支架在复杂病变中的应用武警后勤学院附属医.ppt

全因死亡，心梗，靶血管重建 1.0% (1) 1.0% (1) 全因死亡 0.0% (0) 0.0% (0) 心梗 0.0% (0) 0.0% (0) Q-波心梗 0.0% (0) 0.0% (0) 非–Q-波心梗 0.0% (0) 0.0% (0) 靶血管重建 1.0% (1) 1.0% (1) 靶病变重建 1.0% (1) 1.0% (1) 靶血管失败* 1.0% (1) 1.0% (1) 支架血栓（ARC定义确定/很可能） 1.0% (1) 1.0% (1) 从30天到9月的临床结果 30 天 9 月 PLATINUM QCA (N=100) * 靶血管相关的缺血驱使的靶病变重建，心梗以及心源性死亡 Presented by Ian Meredith, MBBS, PhD at TCT 2010 预先定义有效性终点 9个月支架内晚期丢失-常规病变 0.6 0.4 0.2 0.0 性能目标 = 0.44 mm 0.17?0.25 mm*(N=73) 常规病变支架内晚期丢失 (QCA) (mm) 常规病变：参照血管直径RVD ≥2.5–≤4.25?mm，病变长度 ≤24?mm * Mean ±SD; value of 0.17 with an upper confidence bound of 0.22 mm is significantly less (P0.001) than performance goal based on historical TAXUS Express value (0.41 mm + delta [0.03 mm]) Presented by Ian Meredith, MBBS, PhD at TCT 2010 支架不完全贴壁结果(ISA) 术后ISA* p 0.001 性能目标 SPIRIT III 实验中 PROMUS (Xience V) 数据结果 愈合性 ISA PROMUS? Element?支架 0.0% 0.0% 晚期 ISA (9 月随访) 晚期获得性ISA The SPIRIT Clinical Trials are sponsored by Abbott. (5/88) (4/69) (0/69) (0/69) 5.7% 34.4% 5.8% 支架不完全贴壁 (%) PLATINUM QCA 研究发现最少的支架不完全贴壁可能是由于使用了低弹性回缩的铂铬合金支架平台. Presented by Ian Meredith, MBBS, PhD at TCT 2010 (n=90) (n=88) (n=90) (n=109) (n=145) Presented by Ian Meredith, MBBS, PhD, TCT 2010; SPIRIT III: Stone, et al. JAMA. 2008;299:1903; SIRIUS: Cypher Stent U.S. DFU; ENDEAVOR II: from PMA P060033 FDA Panel Meeting; RESOLUTE: Circulation Journal Aug 3, 2010 (Advance e-Publication, Ahead of Print). PROMUS stent is a private-labeled Xience V? Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation. PROMUS is a trademark of Boston Scientific Corporation or its affiliates. The SPIRIT Clinical Trials are sponsored by Abbott. Acute ISA Results SPIRIT III Trial Late ISA Results Acute ISA Results PLATINUM QCA Trial Late ISA Results Acute ISA Results SIRIUS Trial Late ISA Results Acute ISA Results ENDEAVOR II Trial Late ISA Results Acute ISA Results RESOLUTE Trial Late ISA Results PLATINUM QCA研究中术后和晚期支架贴壁不良(ISA)  与